Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

LTB4 Sweden

LTB4 Sweden
2004 FOUNDED
OOB STATUS
1-10 EMPLOYEES
Liquidation LATEST DEAL TYPE
Description

Developer of small molecule intended to target diseases such as infections and cancer. The company's small molecule is made by using arachidonic acid metabolite leukotriene B4 (LTB4) to innate immunity system for targeting diseases, enabling patients to avail enhanced care without any side effects.

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Discovery Tools (Healthcare)
Primary Office
  • Kornhamstorg 53
  • 111 27 Stockholm
  • Sweden

+46 08-442 00 00
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore LTB4 Sweden’s full profile, request a free trial.

LTB4 Sweden Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Bankruptcy: Liquidation Completed Bankruptcy: Liquidation
1. Early Stage VC Completed Generating Revenue
To view this company’s complete deal history including valuation and funding, request access »

LTB4 Sweden Executive Team (1)

Name Title Board
Seat
Contact
Info
Carl-Johan Dalsgaard Ph.D Managing Director